Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation

Transplant Infectious Disease

Volumn 9, Issue 1, 2007, Pages 16-21

  Ksouri, H ^a   Eljed, H ^a   Greco, A ^a   Lakhal, A ^a   Torjman, L ^a   Abdelkefi, A ^a   Othmen, T Ben ^a   Ladeb, S ^a   Slim, A ^b   Zouari, B ^c   Abdeladhim, A ^a   Hassen, A Ben ^a  

^a CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

^c UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

CMV disease; CMV reactivation; Cytomegalovirus; GVHD; Leukocyte based assay; Preemptive therapy

Indexed keywords

ACICLOVIR; CORTICOSTEROID; CYTOMEGALOVIRUS ANTIGEN PP65; FOSCARNET SODIUM; GANCICLOVIR;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; MALE; NEUTROPHIL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION;

EID: 33846974372     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2006.00171.x     Document Type: Article

References (31)

1. Quan CM, Bowden RA. Clinical aspects of cytomegalovirus infection in marrow transplantation. Marrow Transplant Rev 1993; 3: 17-32.
2. Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 1994; 18: 273-218.
3. Hengel H, Brune W, Koszinowski UH. Immune evasion by cytomegalovirus - survival strategies of a highly adapted opportunist. Trends Microbiol 1998; 6: 190-197.
4. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical application. Clin Microbiol Rev 1998; 11: 533-554.
5. Gerna G, Furione M, Baldanti F, Sarasini A. Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J Clin Microbiol 1994; 32: 2709-2717.
6. Drouet E, Michelson S, Denoyel G, Colimon R. Polymerase chain reaction detection of HCMV in over 2000 blood specimens correlated with virus isolation and related to urinary virus excretion. J Virol Methods 1993; 45: 259-276.
7. Drouet E, Colimon R, Michelson S, et al. Monitoring levels of HCMV DNA in blood after liver transplantation. J Clin Microbiol 1995; 33: 389-394.
8. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
9. Boivin G, Bélanger R, Delage R, et al. Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation. J Clin Microbiol 2000; 38: 4356-4360.
10. Mengelle C, Sandres-Saune K, Pasquier C, et al. Automated extraction and quantification of human cytomegalovirus DNA inwhole blood by real-time PCR assay. J Clin Microbiol 2003; 41: 3840-3845.
11. Razonable RR, Paya CV. The impact of human herpesvirus-6 and 7 infection on the outcome of liver transplant. Liver Transpl 2000; 8: 651-658.
12. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp 65 antigenemia and viral culture. Transplantation 1997; 64: 108-113.
13. Weinberg A, Schissel D, Giller R. Molecular methods for cytomegalovirus surveillance in bone marrow transplant recipients. J Clin Microbiol 2002; 40: 4203-4206.
14. Wolff C, Skourtopoulos M, Horneschmeyer D, et al. Significance of human cytomegalovirus DNA detection in immunocompromised heart transplant patients. Transplantation 1996; 61: 750-757.
15. De ona M, Melon S, Galarraga CM, et al. Comparison of cytomegalovirus pp-65 antigenemia assay and plasma DNA correlation with the clinical outcome in transplant recipients. Transpl Int 2005; 18: 43-46.
16. Sia JG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000; 13: 83-121.
17. Francisci D, Tosti A, Baldelli F, Stagni G, Paluzzi S. The pp65 antigenemia test as a predictor of cytomegalovirus induced end-organ disease in patients with AIDS. AIDS 1997; 11: 1341-1345.
18. Gerna G, Zavattoni M, Percivalle E, Grossi P, Torsellini M, Revello MG. Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection. J Clin Microbiol 1998; 36: 1113-1116.
19. Hadaya K, Wunderli W, Deffernez C, et al. Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol 2003; 41: 3757-3764.
20. Kim CK, Song JH, Kim SM, et al. Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation. Transplantation 2003; 75: 2151-2155.
21. Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36: 813-819.
22. Mori T, Mori S, Kanda Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 431-434.
23. Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted preemptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 765-769.
24. Kanda Y, Mineishi S, Saito T, et al. Pre-emptive therapy against cytomegalovirus (CMV) guided by CMV antigenemia assay after allogeneic haematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437-444.
25. Kanda Y, Chiba S, Suzuki T, Kami M, Yazaki Y, Hirai H. Time course analysis of semi-quantitative PCR and antigenemia assay for prevention of cytomegalovirus disease after bone marrow transplantation. Br J Haematol 1998; 100: 222-225.
26. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia - guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
27. Grossi P, Kusne C, Rinaldo K, et al. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors. Transplantation 1996; 61: 1659-1660.
28. Gerna G, Lilleri D, Zecca M, et al. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2005; 90: 526-533.
29. Nguyen Q, Champlin R, Giralt S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999; 28: 618-623.
30. Reuser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159-1164.
31. Shimokawa T, Morishima Y, Kitaori K, Kato C, Sao H. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors. Int J Hematol 1999; 70: 119-126.